Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Sees Revenues Rise in Q3

SAN FRANCISCO, Oct. 23 - Affymetrix today reported increased revenue for the third quarter of 2002.

 

The company said its total revenue was $72.8 million in the third quarter which ended September 30, up from $55.4 million in the same quarter of 2001. Increased shipments of its GeneChip array and instrument placements accounted for the rise, according to the company. Wafer sales to Perlegen, made at cost, accounted for $4.9 million of revenue.

 

R&D spending stayed approximately flat at $16.7 million compared to the same period a year ago, and the company registered a net income gain of $619,000, or $.01 per basic and diluted share, in the third quarter 2002 compared to a net loss of $4.8 million, or $.08 per share, in the year-ago period.

 

Affy also reported $158.8 million in cash and cash equivalents at the end of September 2002.

 

Click here for more information.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.